Featuring the Medpace Women’s Health Leadership Team, Rujin Ju, MD, MSCR, FACOG, Medical Director, Women’s Health, Aparna Shah, MD, FACOG, Medical Director, Women’s Health, and Beth Tulip, Senior Executive Director, Clinical Trial Management, Women’s Health & Infectious Diseases.
Accelerating the Next Generation of Urinary Tract Infection (UTI) Treatments in Women
Urinary tract infections (UTIs) represent a significant, yet under researched area in women’s health clinical development. Affecting 50-60% of adult women at least once in their lifetime, UTIs are among the most common bacterial infections worldwide. Despite their high prevalence and burden, clinical innovation in this space has lagged, resulting in limited options to address recurrence, treatment failure, and antimicrobial resistance (AMR).
With the rise of multidrug-resistant (MDR) uropathogens and a growing need for patient-centered and individualized therapies, the landscape of UTI drug development is entering a new era. Evolving regulatory expectations, the need for novel endpoints beyond microbiological eradication, and advances in precision medicine are reshaping how Sponsors must approach this indication. Biopharmaceutical companies have a unique opportunity to lead, but doing so requires clinical expertise, regulatory agility, and operational precision.
This Women’s Health Month, Medpace’s Women’s Health Leadership Team explores the key challenges and opportunities shaping the future of UTI drug development in our latest article, “Accelerating the Next Generation of UTI Treatments.”
Clinical and Regulatory Considerations for Advancing Women’s Health Drug Development
Biopharmaceutical companies developing UTI therapies face a pivotal moment in clinical strategy. Success depends on rethinking traditional study designs, expanding beyond legacy endpoints, and anticipating regulatory requirements with scientific precision.
“To bring the next generation of UTI therapies to market, clinical strategy must be matched with flawless execution. Our team understands how to operationalize complex studies—from protocol design to global site activation—so Sponsors can move with speed, precision, and confidence,” shares Beth Tulip, Senior Executive Director of Clinical Trial Management, specializing in Women’s Health & Infectious Diseases, at Medpace.
Advancing UTI drug development requires more than strategy alone. Sponsors must adopt trial approaches that reflect real-world complexity, from defining the right patient populations and selecting meaningful endpoints to engaging regulators early and executing globally.
To explore these key clinical and regulatory considerations, download the full article.
Your Next Breakthrough Starts Here
A Full-Service Approach to UTI Clinical Development
Our cross-functional Women’s Health Leadership Team draws on decades of experience in infectious diseases, vaccines, and women’s health research, ensuring that study designs are both scientifically sound and operationally feasible. With strong relationships across key opinion leaders (KOLs), regulatory agencies, global investigators, and specialized laboratories, Medpace provides biopharmaceutical companies with a connected network that supports every phase of the trial lifecycle.
Our integrated model enables greater alignment, faster execution, and more meaningful outcomes, empowering Sponsors to bring innovative UTI treatments to patients faster. Your next breakthrough in women’s health starts here.
Sources
- Medina, M., & Castillo-Pino, E. (2019). An introduction to the epidemiology and burden of urinary tract infections. Therapeutic advances in urology, 11, 1756287219832172. https://doi.org/10.1177/1756287219832172